Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.

PSMA I&T is a PSMA-targeting radiocompound that serves as a diagnostic agent for prostate-specific membrane antigen-targeted therapy, often coupled with radioactivity.

Rosopatamab MMAE (HUJ-591 MMAE) is an ADC consisting of a PSMA-directed antibody (humanized IgG1 monoclonal antibody against PSMA and monomethylauristatin E (MMAE) for prostate cancer research.

HUHS015 is a potent PCA-1/ALKBH3 inhibitor.

Glu-urea-Lys is a molecular scaffold that targets PSMA and can be used as a prostate cancer imaging agent to study prostate-specific membrane antigens.

Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation. Piflufolastat can be used to prepare piflufolastat F 18 (DCFPyL F-18).

DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

Rosopatamab is a humanized monoclonal antibody targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer. It can be conjugated with radiolabeled isotopes (e.g., 177Lu) via DOTA-NHS ester to form radiopharmaceuticals for targeted therapy. In preclinical studies, 177Lu-DOTA-Rosopatamab combined with the DNA-PK inhibitor Peposertib achieved a 75% complete response rate in prostate cancer mouse models.

Isosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.

CS-0047390, also known as tert-Butyl-DCL, PSMA inhibitor, is a radiopaque peptide reagent.

DUPA(OtBu)-OH is a precursor of DUPA, which is used as a targeting moiety to actively deliver Docetaxel (DTX) for treating Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer, with PSMA showing high affinity for DUPA (Ki = 8 nM).

Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody with potential anticancer activity that can be used to study prostate cancer.

GCPII-IN-1 TFA is a scaffold inhibitor of glutamate carboxypeptidase II (GCPII; PSMA) with a Ki of 44.3 nM.

Biotin-NH-PSMA-617 is a biotinylated derivative of the small molecule PSMA-617, designed to target prostate-specific membrane antigen (PSMA), which is prominently expressed on prostate tumor cells. The biotinylation of PSMA-617 enhances its ability to bind PSMA, making it a valuable tool in the targeting of prostate cancer cells for diagnostic and therapeutic applications.

PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment.

Glu-urea-Lys TFA (1025796-69-3 free base) is a PSMA inhibitor.

BWD is a PSMA ligand (IC50 = 35.86) known for its excellent in vitro stability and high affinity. It enhances tumor uptake and retention, inhibits tumor growth in vivo, and is applicable in cancer research.

MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. It is applicable for research in prostate cancer.

MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. Conjugated with the fluorescent dye AlexaTM488, MDX1201 serves as a probe for near-infrared fluorescence imaging (NIRF) of prostate cancer.

Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. It is capable of binding simultaneously to PSMA on tumor cell surfaces and CD3E on T cell surfaces, leading to significant activation of T cells and the specific destruction of prostate cancer cells.

Defactinib analogue-1 (Compound 7) serves as a ligand for the target protein FAK, and is utilized in the synthesis of PROTAC FAK degrader 1.

SC691 is a PSMA inhibitor that can be labeled with [^68Ga (III)]. SC691 is suitable for imaging and diagnostic studies of prostate cancer.

PSMAligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. When labeled with [18F], PSMAligand 1 serves as a PSMAPET tracer for research related to the diagnosis of prostate cancer.